-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On October 30, Zejing Pharmaceuticals announced that the phase III clinical trial of topical recombinant human thrombin has reached the primary endpoint of the study.
Zejing Pharmaceuticals has submitted an application for pre-BLA clinical communication to CDE to speed up the marketing of recombinant human thrombin for external use
The study is a multi-center, stratified randomized, double-blind, placebo-controlled phase III clinical trial (code name: ZGrhT002), which aims to evaluate the blood capillary and venule oozing of recombinant human thrombin after hepatectomy.
Recombinant human thrombin for external use is a highly specific human serine protease developed based on the complex recombinant protein new drug R&D and industrialization platform of Zejing Pharmaceuticals.
When recombinant human thrombin is used outside of bleeding sites, it can effectively activate platelets, catalyze the conversion of fibrinogen into fibrin, and promote the formation of blood clots, thereby effectively stopping bleeding
According to research reports by companies such as Frost & Sullivan, as the number of surgeries in China increases, the market for surgical local hemostatic drugs will also show a relatively stable growth.
